Replies to post #117736 on Biotech Values

[genisi]

Re: Using IL28B status to dictate treatment

I’m inclined to agree with ThomasS that giving Telaprevir to only the patients who fail to achieve RVR on SoC is likely to backfire in terms of economics (in addition to being bad medicine).

Not all patients just those with CC genotype. I'm sure it will not be used in the US but unfortunately, payors in other countries might want that. I do think that IL28B status should be used but the other way around - not treat patients who will likely not respond to interferon.

[DewDiligence]

Decision Resources thinks Telaprevir and Boceprevir will indeed be widely used in Europe:

http://finance.yahoo.com/news/For-Treatment-of-HCV-Surveyed-bw-3297679268.html?x=0&.v=1

Despite cost pressures, I can’t see these drugs being limited to non-responders or patients with particular IL28 variants as was suggested in the editorial cited in #msg-61764167.